Aslan Pharmaceuticals Ltd
NASDAQ:ASLN
Aslan Pharmaceuticals Ltd
NASDAQ:ASLN
Price:
0.469 USD
4.22%
Updated:
May 28, 2024
Balance Sheet
Balance Sheet Decomposition
Aslan Pharmaceuticals Ltd
Aslan Pharmaceuticals Ltd
| Current Assets | 44.3m |
| Cash & Short-Term Investments | 40.8m |
| Other Current Assets | 3.5m |
| Non-Current Assets | 343.1k |
| PP&E | 340.4k |
| Intangibles | 2.8k |
| Other Non-Current Assets | -10 |
| Current Liabilities | 21m |
| Accounts Payable | 4.4m |
| Other Current Liabilities | 16.6m |
| Non-Current Liabilities | 24.5m |
| Long-Term Debt | 24.5m |
Balance Sheet
Aslan Pharmaceuticals Ltd
Aslan Pharmaceuticals Ltd
Currency: USD
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Cash Equivalents |
51
|
29
|
22
|
14
|
90
|
57
|
|
| Cash |
51
|
29
|
22
|
14
|
90
|
26
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
30
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
1
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
1
|
4
|
4
|
|
| Total Current Assets |
51
|
29
|
22
|
16
|
94
|
61
|
|
| PP&E Net |
0
|
0
|
1
|
0
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
1
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
1
|
0
|
1
|
0
|
0
|
|
| Intangible Assets |
0
|
23
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
51
N/A
|
53
+3%
|
23
-56%
|
16
-31%
|
95
+488%
|
61
-35%
|
|
| Liabilities | |||||||
| Accounts Payable |
4
|
5
|
2
|
2
|
3
|
13
|
|
| Accrued Liabilities |
2
|
3
|
3
|
4
|
3
|
2
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
4
|
0
|
8
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
6
|
8
|
5
|
11
|
6
|
23
|
|
| Long-Term Debt |
10
|
14
|
18
|
15
|
31
|
30
|
|
| Minority Interest |
0
|
0
|
1
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
16
N/A
|
22
+41%
|
25
+12%
|
27
+6%
|
37
+40%
|
53
+42%
|
|
| Equity | |||||||
| Common Stock |
44
|
52
|
61
|
62
|
63
|
63
|
|
| Retained Earnings |
94
|
132
|
179
|
196
|
227
|
278
|
|
| Additional Paid In Capital |
90
|
114
|
117
|
124
|
221
|
224
|
|
| Other Equity |
5
|
3
|
0
|
0
|
0
|
0
|
|
| Total Equity |
36
N/A
|
31
-14%
|
2
N/A
|
10
-522%
|
57
N/A
|
8
-85%
|
|
| Total Liabilities & Equity |
51
N/A
|
53
+3%
|
23
-56%
|
16
-31%
|
95
+488%
|
61
-35%
|
|
| Shares Outstanding | |||||||
| Common Shares Outstanding |
26
|
32
|
38
|
42
|
70
|
70
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
